drugset / Trial / NCT00640861
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
RandomizedTreatment
Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is most effective in treating breast cancer. PURPOSE: This randomized clinical trial is studying the side effects of three different vaccine therapies and comparing the vaccines to see how well they work in treating patients with previously treated stage II or stage III breast cancer.
Timeline
- Start
- 2008-08-28
- Primary completion
- 2015-04-21
- Completion
- 2015-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CpG oligodeoxynucleotide | Oligonucleotide (other) | — | Subcutaneous |
| Subject | HER-2/neu peptide vaccine | Vaccine | — | Subcutaneous |
| Subject | MUC1 Peptide Vaccine | Vaccine | — | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |